Canadian Journal of Urology - Volume 21, Supplement 2 - June 2014 - page 30

© The Canadian Journal of Urology™; 21(Supplement 2); June 2014
5. Roehrborn CG, McConnell JD. Etiology, pathophysiology,
epidemiology, and natural history of benign prostatic
hyperplasia, 8th edn. Philadelphia: Campbell’s Urology, 2002.
6. Jacobsen SJ, Girman CJ, Guess HA et al. Natural history of
prostatism: longitudinal changes in voiding symptoms in
community dwelling men. J Urol 1996;155(2):595-600.
7. Arrighi HM, Metter EJ, Guess HAet al. Natural history of benign
prostatic hyperplasia and risk of prostatectomy. The Baltimore
Longitudinal Study of Aging. Urology 1991;38(Suppl 1):4-8.
8. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms
and male sexual dysfunction: the multinational survey of the
aging male (MSAM-7). Prog Urol 2004;14(3):332-344.
9. Barry M, Fowler FJ, O’Leary M et al. The American Urological
Association symptom index for benign prostatic hyperplasia.
The measurement committee of the American Urological
Association. J Urol 1992;148(5):1549-1557.
10. Speakman M, Kirby R, Joyce A et al. Guideline for the primary
care management of male lower urinary tract symptoms.
BJU Int 2004;93(7):985-990.
11. Rosenberg MT, Staskin DR, Riley J et al. The evaluation and
treatment of prostate-related LUTS in the primary care setting:
the next STEP. Curr Urol Rep 2013;14(6):595-605.
12. Rosenberg MT, Staskin DR, Kaplan SA et al. A practical guide
to the evaluation and treatment of male lower urinary tract
symptoms in the primary care setting. Int J Clin Pract 2007;61(9):
1535-1546.
13. Haidinger G, Temml C, Schatzl G et al. Risk factors for lower
urinary tract symptoms in elderly men. For the prostate study
group of the Austrian Society of Urology. Eur Urol 2000;37(4):
413-420.
14. Gades N, Jacobson D, Girman C et al. Prevalence of conditions
potentially associated with lower urinary tract symptoms in
men. BJU Int 2005;95(4):549-553
15. Burgio KL, Newman DK, Rosenberg MT et al. Impact of
behavior and lifestyle on bladder health. Int J Clin Pract 2013;
67(6):495-504.
16. Stoller ML, Carroll PR. Urology. In: Tierney Jr LM, McPhee SJ,
PapadakisMA, editors. Currentmedical diagnosis and treatment.
43rd ed. NewYork: NY, LangeMedical Books/McGrawHill;2004.
p. 899-940.
17. Beers MH, Berkow R eds: Benign prostatic hyperplasia. In: The
MerckManual, 17th ed. Whitehouse Stastion, NJ, Merck Research
Laboratories, 1999, p. 1829-1831.
18. Scher HI. Hyperplastic and malignant diseases of the prostate.
In: Braunwald E, Fauci AS, Kasper DL, editors. Harrison’s
principles of internal medicine. 15th ed. NewYork, NY: McGraw-
Hill; 2001, p. 608-616.
19. Roehrborn CG, Girman CJ, Rhodes T et al. Correlation
between prostate size estimated by digital rectal examination
and measured by transrectal ultrasound. Urology 1997;49(4):
548-557.
20. NarayanP. Diagnosis andevaluation. In:NarayanP, editor. Benign
prostatic hyperplasia. Gainesville, FL: Churchill Livingstone;
2000, p. 80-87.
21. AUA Practice Guidelines Committee. AUA guideline on
management of benign prostatic hyperplasia. Chapter 1:
diagnosis and treatment recommendations. J Urol 2003;170(2 Pt 1):
530-547.
22. McVary KT, Roehrborn CG, Avins AL et al. Update on AUA
guideline on the management of benign prostatic hyperplasia.
J Urol 2011;185(5):1793-1803.
23. de la Rosette J, Alivizatos G, Madersbacher S et al. Guidelines
on benign prostatic hyperplasia. Arnhem, The Netherlands:
European Association of Urology; 2008.
24. Kaplan SA. Editorial comment on: effect of discontinuation
of 5alpha-reductase inhibitors on prostate volume and
symptoms in men with BPH: a prospective study. Urology 2009;
73:2417.
25. Madersbacher S, Alivizatos G, Nordling J et al. EAU 2004
guide lines on assessment, therapy and follow up of men with
lower urinary tract symptoms suggestive of benign prostatic
obstruction (BPH guidelines). Eur Urol 2004;46(5):547-554.
26. Rehsia S, Shayegan B. PSA implications and medical
management of prostate cancer for the primary care physician.
Can J Urol 2012;19 (Suppl 1):28-35.
27. Roehrborn CG. The utility of serum prostatic-specific antigen
in the management of men with benign prostatic hyperplasia.
Int J Impot Res 2008;20(Suppl 3):S19-S26.
28. Crawford ED, Wilson SS, McConnell JD et al. Baseline factors as
predictors of clinical progression of benign prostatic hyperplasia
in men treated with placebo. Urology 2006;175(4):1422-1427.
29. Kaplan SA, Wein AJ, Staskin DR et al. Urinary retention and
post void residual urine inmen: separating truth from tradition.
J Urol 2008;180(1):47-54.
30. Emberton M, Cornel EB, Bassi PF et al. Benign prostatic
hyperplasia as a progressive disease: a guide to the risk factors
and options for medical management. Int J Clin Pract 2008;62(7):
1076-1086.
31. LevyA, Samraj GP. Benign prostatic hyperplasia: when to ‘watch
andwait’,whenandhowtotreat. CleveClinJMed 2007;74(Suppl3):
S15-S20.
32. Djavan B, Fong YK, Harik M et al. Longitudinal study of men
with mild symptoms of bladder outlet obstruction treated with
watchful waiting for four years. Urology 2004;64(6):1144-1148.
33. Physicians’ DeskReference. 66th ed.Montvale, NJ: ThomsonPDR;
2014.
34. Djavan B, Chapple C, Milani S et al. State of the art on the
efficacy and tolerability of alpha1-adrenoceptor antagonists
in patients with lower urinary tract symptoms suggestive of
benign prostatic hyperplasia. Urology 2004;64(6):1081-1088.
35. Chang DF, Campbell JR. Intraoperative floppy iris syndrome
associated with tamsulosin. J Cataract Refract Surg 2005;31(4):
664-673.
36. Roehrborn CG, McVary KT, Elion-Mboussa A et al. Tadalafil
administered once daily for lower urinary tract symptoms
secondary to benign prostatic hyperplasia: a dose finding study.
J Urol 2008;180(4):1228-1234.
37. Mulhall JP, Guhring P, Parker M et al. Assessment of the impact
of sildenafil citrate on lower urinary tract symptoms in men
with erectile dysfunction. J Sex Med 2006;3(4):662-667.
38. McVary K, MonnigW, Camps JJ et al. Sildenafil citrate improves
erectile function and urinary symptoms in men with erectile
dysfunction and lower urinary tract symptoms associated with
benign prostatic hyperplasia: a randomized, double blind trial.
J Urol 2007;177(3):1071-1077.
39. Stief C, Porst H, Neuser D et al. A randomised, placebo-
controlled study to assess the efficacy of twice-daily vardenafil
in the treatment of lower urinary tract symptoms secondary to
benign prostatic hyperplasia. Eur Urol 2008;53(6):1236-1244.
40. Gacci M, Vittori G, Tosi N et al. Arandomized, placebo-controlled
study to assess safety and efficacy of vardenafil 10 mg and
tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment
of lower urinary tract symptoms secondary to benign prostatic
hyperplasia. J Sex Med 2012;9(6):1624-1633.
41. Ückert S, Oelke M, Stief CG et al. Immunohistochemical
distribution of cAMP- and cGMP-phosphodiesterase
(PDE) isoenzymes in the human prostate. Eur Urol 2006;49(4):
740-745.
42. Oelke M, Giulano F, Mirone V et al. Monotherapy with tadalafil
or tamsulosin similarly improved lower urinary tract symptoms
suggestive of benign prostatic hyperplasia in an international,
randomized, parallel, placebo-controlled clinical trial. Eur Urol
2012;61(5):917-925.
43. Nehra A, Jackson G, Miner M et al. The Princeton III consensus
recommendations for the management of erectile dysfunction
and cardiovascular disease. Mayo Clin Proc 2012;87(8):766-778.
23
Apractical primary care approach to lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH-LUTS)